Oppenheimer analyst Leland Gershell raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $57 from $53 and keeps an Outperform rating on the shares. On Monday, the company reported full-year results for 2025 and provided a business update, with CRBP well positioned heading into multiple important catalysts mid-year 2026, the firm says. Following encouraging results for ‘701 reported at ESMO in October, the company is anticipating regulatory feedback on the path forward in the near term.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals: Advancing Best-in-Class Nectin-4 ADC and Emerging Obesity Franchise Support Buy Rating
- Corbus: Buy Rating Backed by CRB-701 Oncology Potential, Obesity Pipeline Catalysts, and Cash Runway Into 2028
- Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress
- Corbus Pharmaceuticals reports Q4 EPS ($1.25), consensus ($1.58)
- Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook